Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared on LinkedIn:
”The FDA has approved our treatment for hemophilia A and B for two new patient populations following a priority review.
With this approval, children ages 6 to 11 with hemophilia B will have a subcutaneous, non-factor treatment option available for the first time.
Bringing a medicine discovered and developed by Pfizer to the people who need it most—guided at every step by patient need—is an important moment for our teams.
A special thank you to the Pfizer scientists who are continuing to advance care for people with hemophilia, and to the hemophilia patient community who participated in clinical trials that are instrumental to making advancements like this one happen.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 10:52Vaidehi Prasanth: The Role of Viscoelastic Testing in Low- and Middle-Income Countries
-
Jun 9, 2026, 10:37Maria Bruzelius: Hemophilia and Bleeding Disorder in Clinical Practice at NordCoag 2026
-
Jun 9, 2026, 10:02Understanding Factor X Deficiency – ICHCC
-
Jun 9, 2026, 09:49Lee Severin: Why Patients Love Platelet-Rich Plasma
-
Jun 9, 2026, 09:42Lorena Gerlach: Blood Transportation Duty on this Muggy Spring Day
-
Jun 9, 2026, 08:54Shujha Abbas: Understanding the Real Cost of Gene Therapie
-
Jun 9, 2026, 04:47Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
-
Jun 9, 2026, 03:30Fayad Al-Haimus: High-Risk Emergencies and Lifelong Learning at CAEP 2026
-
Jun 9, 2026, 03:14Rucha Patil: A Collaborative Initiative to Transform Rare Blood Disorder Care in Rajasthan